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AMAN~ADINE hydrochloride (adamantanamine, Symmetrel) has been used for several 
years as an antiviral agent effective in prophylaxis against Asian influenza (A,) [ 1,2]. 
Schwab et al [3] first used amantadine in Parkinson’s disease after one patient reported 
remission of her symptoms while taking the drug to prevent influenza. Schwab and 
his associates treated 163 Parkinsonian patients with 100-308 mg of amantadine daily. 
Sixty-six per cent of the group exhibited subjective or objective improvement of 
akinesia, rigidity, and/or tremor, and sustained benefit was noted in over half of the 
patients for a period of 3-8 months. Weeth et al [4] treated 39 patients in a similar 
open trial and found mild to moderate improvement in 23 patients (59 per cent). 
Parkes et al [5] conducted a double-blind crossover trial of amantadine (200 mg/day) 
vs. placebo, each given for a fortnight, involving 37 patients. Thirty-five patients 
completed the trial, and 26 of them expressed a preference for amantadine, five 
preferred placebo and four had no preference. The symptoms improved in order of 
greatest frequency were mobility, tremor, facial expression, speech, general well-being 
and balance. They also evaluated general history, functional disability, walking 
history, appearance, tremor, rigidity, limb dexterity, mood, time to walk 25 yd, and 
time to write a set phrase. All scores except walking history and rigidity improved 
significantly (p < 0.05) when amantadine was compared to placebo. The mean time 
required to walk 25 yd was reduced from 29 to 25 set, and the time to write a set 
phrase decreased from 40 to 37 sec. The only significant difference found between the 
group giving a clear preference for amantadine and the group that did not was age, 
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with the group preferring amantadine having a mean age of 56 yr and the group 
preferring placebo or giving no preference having a mean age of 64 yr. Factors that 
did not influence response to amantadine included severity of disease, stereotactic 
surgery and concomitant medication. 
Fieschi et aE [6] conducted a similar double-blind study involving 18 patients. A 
22-item rating scale and three timed performance tests were used to evaluate the 
effects of placebo and amantadine. They found a more marked placebo effect and 
also a greater effect on rigidity than had been reported by Parkes and his associates. 
Hunter et al [7] evaluated 17 patients in a double-blind trial. Four of the patients 
received placebo throughout the 8 weeks of the trial, four received only amantadine 
(200 mg daily), four received placebo the first 4 weeks and amantadine the final 4 
weeks, and four received amantadine the first 4 weeks and placebo the final 4 weeks. 
Weekly assessment of physical signs and functional disabilities revealed small but 
significant differences in some physical signs and no significant differences in disability 
scores. All but one of the measures of individual signs were improved, but no individual 
measure was significantly changed. 
Every trial of amantadine to date has found evidence of at least some improvement 
in patients with Parkinson’s disease. Patient acceptance has been excellent and the 
incidence of significant toxic effects has been low in the 20&300 mg/day range [5]. 
However, estimates of its efficacy have been inconsistent and there is a paucity of 
information on the quantitative effect of amantadine on various parameters of 
neurological function. 
Our laboratory has been engaged for several years in the development of a battery 
of tests for the quantitative evaluation of neurological function. We feel that such 
tests are well suited for use in evaluating therapy in Parkinson’s disease. Not only 
are these measures recorded on interval or ratio scales and sensitive to relatively 
slight changes, they also offer the advantage of assessing a wide range of neurological 
function, including measures of the many components of motor, sensory and psy- 
chological performance. It is therefore possible to determine the magnitude of 
effectiveness of the treatment program and the specific nature of improvement that 
can be expected. The battery of tests is administered by trained paramedical personnel. 
They are specifically instructed not to discuss the effect of any medication which the 
patient might be taking, and do not have access to previous scores. Consequently 
the data are as objective as can be obtained with this type of testing. 
A feature complicating the interpretation of most amantadine trials to date involves 
the concurrent use of standard anti-Parkinsonian medications. Consequently, we 
have attempted to establish the efficacy of amantadine alone, since it may have a 
similar mechanism of action to standard medications. Finally, we felt it important to 
determine in a comprehensive fashion the effects of amantadine on mental state and 
activities of daily living, functions upon which the patient primarily determines the 
preference for a treatment when it is non-toxic. 
PATIENTS AND METHODS 
Patients 
Consecutive patients applying for anti-Parkinsonian therapy at The University of 
Michigan Medical Center were asked to participate in the proposed drug trial. The 
trial design was described and they were told that they would be asked to reduce their 
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present medication to the lowest tolerable level, preferably terminating all other 
medications for the 12 weeks of the study. Patients were screened to eliminate those 
having concurrent medical problems, questionable diagnoses, or physical disabilities 
making it impossible for them to stand or transfer to and from a wheel-chair or to 
commute to the regular re-evaluation examinations. Patients who had undergone 
stereotactic surgery also were eliminated. Otherwise, patients were accepted irrespec- 
tive of sex, age, or duration of illness. In total, three patients were eliminated because 
of questionable diagnosis, three because of previous stereotactic surgery, four because 
they were satisfied with their current therapy, and one because he later insisted that 
he would be unable to tolerate the subsequent evaluation examination. Of the final 
42 patients accepted in the study, there were 26 males and 16 females, their ages 
ranging from 48 to 85 yr (mean 65 yr). The average duration of their disease was 8 yr. 
Thirty-six of the patients were able to discontinue all other traditional anti-Parkin- 
sonian medications prior to and throughout the study. Of the six patients remaining 
on anti-Parkinsonian therapy, four remained on a trivial dosage (two patients on 
PagitaneR, 1.25 mg q.d.; one, on ArtaneR, 2 mg q.d.; and one, on ParsidolR, 50 mg 
once per week); whereas, two patients required a larger dosage (one patient, ArtaneR, 
6 mg q.d., and the other Cogentin R, 6 mg q.d.). Because no significant differences 
were found when the data were analyzed with and without these patients, they have 
been included in all the analyses. 
Trial design 
Patients were instructed to taper their present medications, discontinuing anti- 
histamines immediately and tapering anticholinergics over a 1 week period. Patients 
who could not tolerate this change were instructed to choose from their medication 
one tablet twice daily, establishing a routine for at least 1 week prior to their second 
visit. On the average, patients called the neurologists (Drs. Walker and Tourtellotte) 
three times during the ‘tapering period’ and each time the patient was asked: ‘Can 
you tolerate being just like you are, with no additional medication, for 6-12 weeks; 
that is, can you tolerate being placed on placebo medication?’ Prior to removal of 
their pretrial medication, the battery of qualitative and quantitative neurological 
examinations were administered to each patient. Various laboratory tests (serology, 
hematocrit, white blood cell count and differential, BUN, SGOT, alkaline phos- 
phatase and urinalysis) were obtained. 
Four weeks after their initial visit each patient returned, having been successfully 
off all medication or on a stable regimen. An interval history was obtained and their 
neurological function re-evaluated. Patients were then randomly divided into two 
groups with one group given 100 mg amantadine twice daily and the other group 
given placebo capsules of similar taste and appearance. Three weeks later, patients 
returned for re-evaluation. An interval history was obtained and neurological function 
evaluated. Unused capsules were returned and later counted and identified. The 
amantadine and placebo groups were then reversed. Three weeks later, patients 
returned for the final trial evaluation. An interval history was obtained, neurological 
function evaluated, and unused capsules returned. A summary of the experimental 
paradigm is shown in Table 1. It is emphasized that the same 42 patients received 
both treatments. 
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TABLE 1. EXPERIMENTAL PARADIGM 
Group 
No. of Medication taken during week 
patients 1 2-5 6-8 9-l I 
1 21 S 0 A P 
2 21 S 0 P A 
S =Standard anti-Parkinsonian medication being used upon entry to trial. 
O=Off all medications. 
P = Placebo. 
A = Amantadine. 
Assessment 
Both qualitative and quantitative measures of the patients’ functional capacity 
were obtained throughout the trial. The clinical evaluations were obtained and the 
quantitative neurological examination was administered on four separate occasions; 
while the patients were on their standard medications, while they were off all medica- 
tions or tapered to their lowest tolerable level, and while they were on placebo and 
amantadine. The Simulated Activities of Daily Living Examination (SADLE) and 
the Neuro-Psychological Examination (NPE) described below were not administered 
during the patients’ initial visit while they were on their conventional medications 
but were administered on all subsequent visits. A brief summary of the assessment 
measures follows: 
(A) Qualitative measures 
(1) Patients’ impression 
Patients were asked to subjectively evaluate any change in condition after both 
placebo and amantadine treatment. Each patient determined (1) whether the drug 
had been useful, and (2) whether he was worse, no different, 25 per cent improved, 
50 per cent improved, 75 per cent improved, or completely well after treatment 
compared to his pretreatment condition. Patients were also asked to specify in what 
ways, if any, their condition had changed. 
(2) Neurologists’ overall subjective impression 
The ‘blinded’ neurologists were asked to subjectively evaluate their preference for 
the two treatments. Such a subjective evaluation included their clinical observations 
as well as their interpretation of reported side effects, of the patients’ subjective 
impressions, and of qualitative evaluation forms described below. 
(3) Qualitative evaluation 
Two subjective evaluation forms were filled out by the same ‘blinded’ neurologists 
throughout the trial. The first evaluation required the neurologists to categorize the 
individual patient’s functional disabilities with respect to walking, dressing, hygiene, 
eating and feeding, and speech using the disability scales shown in Appendix A [8]. 
A total functional disability score was obtained by adding the scores for the specific 
areas. The second evaluation required the neurologists to evaluate relevant physical 
signs (i.e., tremor, rigidity, cogwheeling, weakness, finger dexterity, succession 
movements, bradykinesia, foot tapping, associated movements, rising, posture, 
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stability and gait) using the traditional classifications of normal, minimal, mild, 
moderate and severe. 
(4) Motion pictures of patients performing a routine series of tasks were recorded 
at each examination period as a permanent visual record of the patients’ motor 
capabilities. The movie secjuence included a record of the patient sitting at rest in a 
chair; performing a series of rapid succession movements (right and left); performing 
a series of coordinated movements, including picking up a glass and bringing it to 
his mouth (right and left); tapping his feet; repeatedly rising and sitting in a chair; 
standing without support; walking: and turning. 
(B) Quantitative measures 
(1) An Activities of Daily Living (ADL) test battery was administered to assess 
the patients’ performance on standardized tests which simulate acts of daily living 
(SADLE). The time necessary to complete individual tests such as putting on a shirt, 
tying a bow, using buttons, dialing a telephone, manipulating a safety pin, opening 
an envelope, opening a door, vocalizing, etc., was recorded. The test names along 
with their abbreviations and a brief description of each test are shown in Appendix B. 
These tests were administered by a trained ‘blind’ occupational therapist (J. A. Sagath) 
whose only responsibility was to obtain data. She was instructed not to discuss the 
effect of medication and she had no access to previous scores. 
(2) A Clinical Quantitative Neurological Examination (CQNE) was administered 
to each patient. This battery of motor and sensory tests assesses basic abilities including 
strength, steadiness, simple reaction time, hand and foot speed, hand and foot 
coordination, psychomotor coordination, manual and finger dexterity, gait and 
station, and fatigue. The sensory tests include evaluation of visual acuity, touch 
sensation, vibration sensation, 2-point discrimination, and position sense. These tests 
are more completely described in previous articles [9-Ill, and more recently in 
Potvin’s Ph.D. Thesis (see footnotes in Appendix B and C). A brief description of 
each test appears in Appendix C, including the measures, the units, and the instru- 
mentation. These tests were administered by a trained ‘blind’ physical therapist 
(Kazmierczak or Shimp) whose only responsibility was to obtain data. (She was 
instructed not to discuss the effect of medication and she had no access to previous 
scores.) 
(3) A neuro-psychological test battery was administered to evaluate specific 
higher and lower level cerebral functions (NPE). 
The tests included the Peabody Picture Vocabulary test, a color naming and recog- 
nition subtest from the Eisenson test for Aphasia, a double simultaneous (face-hand) 
stimulation test, a discrimination test of right-left and body parts, the Raven Coloured 
Progressive Matrices test, the Hooper Visual Organization test, a written and oral 
digit substitution test, and the Wechsler Adult Intelligence Scale subtests (digit span, 
digit-symbol, picture completion, picture arrangement, and object assembly). These 
tests were administered by a trained ‘blind’ psychologist (A. Smith or R. Champoux) 
whose only responsibility was to obtain data. He was instructed not to discuss the 
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effect of medication and he had no access to previous scores. The results of this 
portion of the trial will be reported more completely elsewhere. 
Control subjects 
Normative data previously were established for all of the quantitative tests except 
the activities of daily living (SADLE) items using 80 young asymptomatic subjects, 
mean age 21.5 yr, S.D.=2.2 yr. Normative data for the (SADLE) were obtained 
using 23 spouses of patients participating in the amantadine trial. The mean age of 
the control group was 61.5 yr, S.D.=3.8 yr. Normal scores are included in Tables 
4 and 7. 
Patients’ impressions 
RESULTS 
Patients were asked to evaluate their condition at the end of placebo and amantadine 
treatment. Responses to the question: ‘Was the drug useful to you?’ are summarized 
in Table 2 for both placebo and amantadine treatment. There was a significant 
tendency for amantadine treatment to be subjectively classified as useful by the 
patients as compared to placebo treatment (p<O.Ol using the McNemar test for 
correlated proportions), with 64 per cent of the patients responding favorably to 
amantadine treatment as compared to 21 per cent of the patients responding favorably 
to placebo treatment. 
TABLE 2. RESULTS OF ADMINISTRATION OF PLACEBO AND AMANTADINE 
TO 42 PARKINSONIAN PATIENTS. PATIENTS’ OVERALL SUBJECTIVE IMPRESSIONS. 
PATIENTS’ RESPONSE TO: ‘WAS THE DRUG USEFUL TO YOU? 
Patients’ response after Patients’ response after 
placebo treatment amantadine treatment 
Useful Not useful Row total 
Useful 7% ( 3)* 14% (6) 21% ( 9) 
Not useful 57% (24) 21% (9) 78% (33) 
Column total 64% (27) 35% (IS) 
*Indicates 7% (3 patients) found the drug useful while on placebo 
treatment and useful while on amantadine treatment. 
The patients’ subjective overall evaluations of change in condition are summarized 
in Fig. 1, demonstrating that a greater number of patients responded ‘worse’ or ‘no 
change’ following placebo treatment than following amantadine treatment while 
fewer patients responded they were improved following placebo treatment than 
following amantadine treatment. 
Patient impressions of specific improvements are summarized in Table 3. Examin- 
ation of this table suggests that administration of amantadine did not result in 
improvement in any one specific area, although the most frequent patient responses 
included improved walking, faster movements, less tremor, increased ability to get 
out of a chair and bed, and clearer speech. Patient impressions after receiving placebo 
treatment most frequently involved decreased tremor. 
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PLACEBO TREATMENT 
FIG. 1. Patients’ overall subjective evaluations. Patients’ responses to the question: 
‘Are you worse, no different, 25 per cent improved, 50 per cent improved, 75 per 
cent improved, or completely well after treatment as compared to your pretreatment 
condition? 
Neurologists’ overall subjective impressions 
The subjective clinical impression was that amantadine had a moderate but positive 
effect upon the majority of patients as compared to placebo treatment. Using infor- 
mation recorded during the interval histories, the neurologists were asked to dis- 
tinguish between placebo and amantadine, responding to the question ‘Which is the 
better drug in the treatment of the individual patient?’ Amantadine was preferred 
over placebo for 74 per cent of the patients (31 patients). Utilizing the sign test, this 
is a significant impression (p < 0.01). 
Qualitative evaluation sheets 
General Functional Disability Scores are shown in Fig. 2, comparing average 
scores obtained while the patients were on their previous medication, pretreatment, 
placebo and amantadine. These qualitative measures of activities of daily living 
indicate by inspection that amantadine treatment has a modest but positive effect, 
being better than placebo treatment, pretreatment, or the previous medication in 
each of the categories evaluated. Utilizing the sign test a significant difference (p < 0.05) 
between amantadine and placebo treatment existed for walking, hygiene, eating and 
D 
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TABLE 3. PATIENTS’ ~~B~CTIVE EVALUATION. PATIENTS' RESPONSES ~0: 
‘HOW ARE YOU SPECIFICALLY IMPROVED?’ 
A. Patient Impressions of Improvement after Receiving Amantadine* 
No. of 
How are you improved (if at all?): patients 
Walking improved 13 
Walking farther and faster 6 
Moving faster 9 
Tremor less 9 
Getting out of a chair and bed easier Y 
Speech clearer 7 
Talk faster 2 
Able to feed self better 4 
Less tired 4 
Dress easier 3 
Mist: more strength, turnover in bed better, more confident, 
more enthusiasm, better balance, more alert, better writing, 
less stiffness, posture better, read better 19 
B. Patient Impressions of Improvement after Receiving Placebo 
No. of 
How are you improved (if at all?): patients 
Tremor less 6 
Walking improved 3 
Mood better 2 
Mist: more strength, less tired, speech clearer, able to do more, 
balance better, more alert, able to put hand in back pocket, 
more mobile, feel better generally, less constipated, sleep better 10 
*Patients asked, ‘In what specific ways are you better, if any?’ The 
categories listed are paraphrased reductions of the patients’ own 
comments. Some patients are entered into several specific categories of 
improvement. 
feeding, speech and total disability score, but not for dressing. Additional subjective 
evaluations using the more detailed qualitative evaluation forms are summarized in 
Fig. 3. Mean scores bjr inspection indicate that amantadine treatment was preferable 
over placebo treatment for 17 of the 18 items evaluated. The greatest improvement 
again was recorded for the evaluation of gait. Significant improvement of amantadine 
over placebo (sign test, p < 0.05) was found for tremor of the head, succession move- 
ments of the upper extremities, weakness of the lower extremities, rising from a chair, 
posture and gait. Only foot tapping showed more patients worsened on amantadine, 
but this was not significant. 
Quantitative measures 
Simulated activities of daily living exrmination (SADLE). Results of the tests of the 
SADLE are summarized in Table 4. Scores are shown for 23 asymptomatic spouse 
controls and 42 parkinsonian patients prior to treatment (after the patients had been 
tapered to minimal or no medication). In addition, scores obtained following adminis- 
tration of placebo and amantadine are shown for both treatment groups separately 
as well as the combined group. The results of the paired t-tests comparing placebo 
to amantadine treatment for each of the test items also are shown. Fourteen of the 
19 items indicate significantly better patient performance after amantadine treatment 
when compared to placebo treatment for the combined groups. Inspection of the 
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FIG. 2. General functional disability scores comparison of previous medication 
(entry), pretreatment placebo and amantadine. Neurologists’ evaluations by inquiry 
of activities of daily living, mean scores for all 42 patients. (See Appendix A for 
data sheet used.) 




















































FOG. 3. Evaluation of relevant physical signs of Parkinsonism after placebo and 
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remaining five test items reveals that all but one (envelope) favor amantadine treat- 
ment. Examination of the scores for treatment Groups 1 and 2 indicates no striking 
differences between the two groups. 
Table 5 summarizes the results of a sign test analysis, comparing the number of 
patients better on amantadine treatment to the number better after placebo treatment 
for the individual and combined treatment groups. Any measurable improvement or 
deterioration in performance was regarded as a change for the purposes of this analysis. 
Ten of the 19 test items demonstrate that a significantly greater number of patients 
performed better after amantadine treatment than after placebo treatment for the 
combined groups. Inspection of the remaining nine tests demonstrates a similar 
trend but not at a significant level. Separate comparison of treatment Groups 1 and 2 
indicates that Group 2 (treated with placebo before amantadine) demonstrated a 
more significant preference for amantadine than did Group 1 (treated with amantadine 
before placebo). This finding may be interpreted as an indication that learning effects 
in these tests, although slight, are significant. However, the nature of the crossover 
trial minimizes this effect when the two treatment groups are combined for analysis. 
In order to determine the magnitude of response to placebo and amantadine, the 
SADLE test scores are better expressed as a percentage of age matched normal 
TABLE 6. SUMMARY OF SIMULATED ACTIVITIES OF DAILY LIVING 
EXAMINATION (SADLE) TEST-SCORES FOR THE COMBINED GROUPS SHOWN IN 
TABLE 4 EXPRESSED AS PERCENTAGE OF NORMAL FUNCTION. 
PRETREATMENT,PLACEBO AND AMANTADINE 
Test 
Percentage of normal 





























































*Indicates significance at the 0.10 level, placebo vs. amantadine (paired 
f-test). 
tmdicates significance at the 0.05 level, placebo vs. amantadine (paired 
t-test). 
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function (,~~~!~” x 100, with scores expressed in terms of tasks accomplished 
per second except for vocalization and drinking when the inverse ratio was used). 
See Table 6. It is then possible to determine how effective amantadine is in bringing 
the patient back to normal function. The average percentage of normal function for 
all 19 of the SADLE tests was 31.9 per cent pretreatment, 30.8 per cent after placebo 
treatment and 39.6 per cent after amantadine treatment. 
Clinical quantitative neurological examination (CQNE) 
A summary of the CQNE results is shown in Table 7. Control scores obtained 
from 80 asymptomatic young adults (mean age=22.4 yr) are compared to patient 
scores upon entry (previous medication), pretreatment (no or minimal medication), 
and after placebo and amantadine treatment. Examination of the paired t-test analyses 
indicates a significant preference for amantadine in the following test areas: 
Strengtlz of movements 
1. Grip strength, dominant and nondominant. 
2. Shoulder abduction, dominant. 
Coordination of movements 
1. Speed-coordination of hand, dominant and nondominant. 
2. Index of performance, dominant and nondominant hand. 
3. Rotary pursuit tracking, dominant and nondominant hand. 
4. Finger dexterity, Purdue pegboard and pencil rotation, dominant and non- 
dominant. 
5. Speed-coordination of foot, forward and side step, dominant and nondominant. 
6. Index of performance, dominant and nondominant foot, forward and side step. 
Station and gait 
1. Standing, eyes open, two legs together. 
2. Standing, eyes closed, two legs together. 
3. Tandem gait, walking without and with support. 
Results indicate specific improvement in all of the coordination tests, with improve- 
ment in some of the strength, station and gait tests. Significant changes were not 
observed for those tests measuring sensation (vision, touch, vibration, position or 
2-point discrimination), steadiness, simple reaction time, speed of hand, strength of 
the lower extremities, or fatigue with the exception of increased fatigue as measured 
by one of the foot coordination fatigue tests. Comparison to the remainder of the 
fatigue tests suggests that this isolated finding is of little significance. 
The results of a sign test analysis upon the CQNE scores after placebo and amant- 
adine treatment are summarized in Table 8. As before, any measurable improvement 
or deterioration was regarded as a change for the purposes of this analysis. Findings 
are similar to those using the t-test, indicating improved performance following 
amantadine treatment in some of the strength tests, the coordination tests, and 
unsupported tandem gait test, and two of the fatigue measures. A statistically signifi- 
cant difference also was found for amantadine treated patients for one of the vibration 
tests. This was the only significant sensory finding. 
These results obtained from the SADLE and CQNE test batteries confirm the 
findings obtained with the subjective and qualitative methods (patients’ impressions, 
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neurologists’ overall impression, functional disability scores, and evaluation of 
relevant physical signs). There is no question that amantadine is a better treatment 
than placebo for Parkinson’s disease. 
In order to simplify the analysis of the CQNE data and to express it in more 











Vision (visual acuity). 
Strength (grip, wrist dorsifexion, shoulder abduction, foot dorsiflexion, hip 
flexion). 
Steadiness (hole steadiness, supported and unsupported). 
Reaction time (simple reaction time). 
Speed (speed of hand, speed of foot). 
Coordination (speed coordination of hand and foot; index of performance, 
hand and foot; rotary pursuit; Purdue pegboard; pencil rotation). 
Fatigue (grip strength fatigue, hip strength fatigue, speed of hand and foot 
fatigue, speed-coordination of hand and foot fatigue). 
Station (standing: eyes open, two legs and one leg; eyes closed, two legs and 
one leg). 
Gait (tandem gait, supported and unsupported). 
Sensation (touch, hand and toe; vibration, finger and toe; position, upper and 
lower extremities; 2-point discrimination). 
The overall CQNE findings can be summarized by first expressing all of the test 
scores as a percentage of normal function (n~ra~~!~~~~re X 100 or n;;$;crry x 100 
when better performance reflects a lower score, e.g., vibration sense), and then 
averaging all of the test scores representative of a functional category. For example, 
after expressing all of the strength test scores for a given patient in terms of 
‘percentage of normal function’, the measure of grip strength, wrist dorsiflexion, 
shoulder abduction, etc., can be averaged to obtain a single measure of STRENGTH. 
The actual measures, expressed as percentage of normal function, are shown in 
Table 9. A summary of the change in percentage of normal function, comparing 
placebo and amantadine scores to pretreatment scores for the functional categories is 
shown in Fig. 4. The functional category demonstrating the most significant improve- 
ment is coordination, with strength and gait also demonstrating improvement, 
significant at p < 0.05. None of the other functional categories show significant change. 
Neuro-psychological test battery (NPE) 
Of the 14 NPE tests administered, only one, the digit-symbol substitution test, 
demonstrated a significant difference between placebo and amantadine treatment. 
The digit-symbol test requires the subject to substitute a symbol for a digit, writing 
the symbol on a piece of paper. As such, the test does have significant motor output 
and is more than a measure of purely cognitive function. Moreover, of all the subtests 
in the Wechsler Adult Intelligence Scale, digit-symbol is most sensitive to changes in 
fine manual dexterity and visual-motor coordination. Performance following amant- 
adine treatment was significantly better than after placebo treatment at the p < 0.05 
level. A comparison after placebo and amantadine treatment of those tests having 
quantitative measures is shown in Fig. 5. 
E 
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TABLE 9. SUMMARY OF CLINICAL QUANTITATIVE NEUROLOGICAL EXAMINATION (CQNE) TEST SCORES 
FOR THE COMBINED GROUPS SHOWN IN TABLE 7 EXPRESSED AS PERCENTAGE OF NORMAL FUNCTION’. 













Percentage of normal Paired t-test 
Difference between 
Pretreatment Placebo Amantadine amantadine and placebo 
91.0 87.4 88.1 0.70 
60.0 62.6 64.4 2.69t 
51.1 54.9 53.6 -0.55 
62.2 66.4 67.3 0.89 
58.3 60.6 62.4 1.20 
40.9 42.0 47.9 5.09* 
91.7 93.7 94.3 0.40 
44.2 48.3 49.2 0.48 
41.1 40.1 44.6 2.22t 
75.8 75.3 76.6 0.66 
Total extremity upper 65.1 66.9 68.5 2.24t 
Total lower extremity 59.1 61.4 63.3 1.44 
Combined upper and 
lower extremity 62.1 64.2 65.9 2.02t 
tIndicates significance at the 0.05 level. 
$Indicates significance at the 0.01 level. 
‘As established by test scores obtained from 80 young adults. 
Factors influencing response to amantadine 
The 27 patients who responded favorably to amantadine treatment were compared 
to the 15 patients who did not. The age (66 yr vs. 64 yr), sex (63 per cent males in 
group responding vs. 62 per cent males in group not responding), and treatment 
group assignment (54 per cent of patients responding to amantadine in Group 1) 
were similar for both groups, The duration of disease was greater for those patients 
responding to amantadine than those who did not (10 yr vs. 5 yr; p < 0.05). In addition, 
the degree of disability as determined by the neurologists was greater in those patients 
responding to amantadine than those who did not, although this difference was not 
significant. The average stage of the group responding to amantadine was 3.1 while 
the average stage of the group that did not respond was 2.5. (See Hoehn et al [12] 
for the stages of Parkinsonism based on the level of clinical disability.) Subjective 
comparison of the six patients using concurrent anti-Parkinsonian medications 
suggests greater improvement for this group of subjects as compared to those patients 
using no concurrent medication. The small sample size (six patients) makes statistical 
analysis inappropriate. Evaluation of the General Disability Scale for these six patients 
indicates an improvement of 24 per cent after amantadine treatment when compared 
to pretreatment scores contrasted to a 9 per cent improvement for the remaining 
patients. However, analyses of quantitative data indicate no significant changes in 
the results when these six patients are not included in the evaluation. 
Side effects 
Treatment was not associated with important adverse side effects in any of the 
cases. As noted by other investigators [13], more side effects were reported with 
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FIG. 4. Clinical quantitative neurological examination (CQNE) (functional 
categories). Comparison of percentage of normal function of placebo and amantadine 
treated patients when compared to pretreatment scores. 
placebo treatment than with amantadine treatment. Results are shown in Table 10. 
Eight patients had a transient increase of leukocytes in their urine while on amantadine, 
although no patient had more than 15 cells per high power field. There were no 
symptoms of urinary tract infection. 
DISCUSSION 
Tithe qualitative and quantitative measures employed in this trial demonstrate that 
amantadine is superior to placebo in the treatment of Parkinson’s disease. Moreover, 
the benefit appears to be greater than that afforded by the patients’ standard medi- 
cations used upon entry to this study. 
Walking, as evaluated by both patients and neurologists, improved more than the 
other subjective measures, but hygiene, eating, feeding and speech also improved. 
Clinical neurological evaluation demonstrated improvement in tremor, weakness, 
succession movements, rising, posture and gait. This broad improvement contrasts 
with the findings of Hunter er al [7] who reported only a small beneficial effect on 
physical signs and no significant effect upon functional abilities. The larger size of 
our series (42 vs. 12) may account for this disagreement. 


























n.s.= not Significant 
_ PLACEBO 
////l//L AMAN~ADINE 
FIG. 5. Neuro-psychoiogical examination (NPE). Effect of placebo and amantadine 
treatment on Parkinsonism. 
Quantitative analysis of a broad range of motor, sensory, and cognitive tests revealed 
significant improvement only in the motor sphere. The most marked improvement 
was noted in tasks associated with fine finger manipulations, gross arm and leg 
movements, station, and gait. Overall strength also improved slightly, but significantly. 
The improvement in these basic abilities corresponded with improvement in the tests 
of simulated activities of daily living, a battery of tests designed to mimic tasks which 
patients must carry out in order to care for themselves. The agreement with subjective 
assessment establishes the consensual validity of the quantitative measures. Note that 
the specific areas of improvement could not have been determined without a com- 
prehensive battery of motor, sensory, and psychological tests. 
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TABLE 10. NUMBER OF PATIENTS REPORTING SW EFFECTS DURING 





















































Another important finding resulting from the use of a battery of tests is the security 
of knowing that the drug does not produce a decrement in performance in those 
areas not specifically affected. Talland [14], for example, found a diminution in certain 
cognitive functions (verbal rate, learning, Necker cube oscillation) in Parkinsonian 
patients using ArtaneR or ParsidolR compared with patients not using these drugs. 
We think a battery such as ours would be useful in evaluating any drug for the 
detection of deleterious nervous system side effects. 
We emphasize that all mention of improvement has been expressed in terms of 
statistical significance. As is often the problem in any study involving a relatively 
large number of patients, statistically significant findings may result from small 
changes, so small as to be of little biological significance. Alternatively, in studying 
basic abilities such as strength, reaction time, or hand coordination, it is difficult to 
determine what effect small changes in these items will have upon the overall functional 
capacity of the patient. One major advantage of the quantitative measures expressed 
in interval or ratio units when contrasted with the subjective scales expressed in 
ordinal units involves the capability of expressing the patients’ performance as a 
percentage of normal function. This permits the physician to establish more meaning- 
ful estimates involving the actual degree of improvement that can be expected following 
a specific drug trial. In this study, many of the measures evaluated in this fashion 
improved only slightly. However, the average increase (from 31.9 to 39.6 per cent of 
normal function) following amantadine treatment for the tests of simulated activities 
of daily living (Table 6) is probably of considerable biological significance to the 
individual patient. 
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Another way of establishing drug efficacy is to compare a new drug with standard 
medications. In every category tested, amantadine performed as well as or better 
than the patients’ standard, optimal drug therapy, though few of the comparisons 
reached statistical significance. 
SUMMARY 
A double-blind crossover trial of amantadine vs. placebo was carried out involving 
42 patients with Parkinson’s disease: 64 per cent of the patients on amantadine 
experienced subjective improvement compared to 21 per cent on placebo. A com- 
prehensive battery of qualitative and quantitative tests was carried out on each patient 
on entry to the study, after previous standard treatment was discontinued or reduced 
to a minimal tolerable dose, while on placebo, and while on amantadine, at 3 
week intervals. Almost all relevant symptoms and physical signs improved, and the 
neurologists judged amantadine superior to placebo in 74 per cent of the patients. 
Quantitative measurement revealed significant improvement in 10 of 19 tests of 
simulated activities of daily living, in several tests of strength and station, and in all 
tests of coordination and gait. When the amantadine scores were compared to the 
placebo scores, an average improvement of 29 per cent occurred in the simulated 
activities of daily living, 14 per cent in tests of coordination, 11 per cent for gait and 
3 per cent for strength. Sensation and neuropsychologic performance were unaffected 
and side effects were minimal. Comparison of amantadine scores with entry scores 
obtained when the patients were on standard anti-Parkinsonian medications suggested 
that amantadine may also be superior to classical medications. The response to 
amantadine was not related to age, sex, or severity of disease, but those who responded 
were found to have a significantly longer duration of illness. Amantadine is a non- 
toxic, easily administered drug useful in the treatment of Parkinson’s disease. 
It should be emphasized that the quantitative tests used in this study yielded 
interval data. This resulted in more valid comparisons with normal, particularly when 
expressed in terms of the percent of the age-matched normal function. 
Finally, this is the first report which describes a battery of quantitative tests 
designed to measure in part the effect of a drug on activities of daily living. It could 
be that these results were the most indicative of a significant effect in this experiment, 
since it is an improvement in the accomplishment of activities of daily living, not 
neurological tests, by which a patient with Parkinsonism bases his judgement of the 
effectiveness of a non-toxic treatment. 
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APPENDIX A 
GENERAL DISABILITY SCALES 
Neurologists’ Evaluation by Inquiry of Activities of Daily Living [8]. 
Always walks alone 
Normal 
Scale A. WALK~G 
0 
Gait only slightly deviant from normal in quality and speed; turning is the most difficult 
task, posture essentially normal 1 
Quality of gait is poor and rate is slow; posture moderately affected; there may be a 
tendency toward mild propulsion; turning is difficult 




Sometimes walks alone 
Walks short distances with ease; walking outdoors is difficult but often accomplished 
without help; rarely walks longer distances alone 
Walks from room to room with only moderate difficulty; may occasionally walk 
outdoors without assistance 
4 
5 
Walks from room to room without assistance, but moves slowly and uses external 
support; never walks alone outdoors 
Never walks alone 
6 
Requires potential help indoors and active help outdoors 7 
Requires moderate help indoors; walks outdoors with considerable help 8 
Needs considerable help even for short distances; cannot walk outdoors with help 9 
Cannot walk at all, even with maximum assistance 10 
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Complete self help 
Normal 
Scale B. DRESSING 
Dress self completely with only slightly more time and effort than normal 
Dress self completely with slowness and great effort 
Requires partial assistance 
Handles all dressing alone with the exception of fine activities (tie, buttons) 
Performs more than half of dressing activities alone, with considerable effort and 
slowness 
Performs about half of dressing activities independently 
Performs only gross dressing activities alone (hat, coat) 
Requires complete assistance 
Gives considerable help through bodily movements 
Can give some help through bodily movements 
Movements of patient neither help nor hinder assistant 
Patient is a hindrance rather than a help to assistant 
Complete self help 
Normal 
Scale C. HYGIENE 
Hygiene maintained normally, with exception of slight slowness 
Hygiene activities are moderately time-consuming; no substitute methods; few accidents 
Hygiene maintained independently, but with effort and slowness; accidents are not 
infrequent, may employ substitute methods 
Requires partial assistance 
Manages most of personal needs alone; has substituted methods for accomplishing 
difficult tasks (electric razor) 
Requires assistance for some tasks not difficult in terms of coordination 
Requires assistance for half of toilet needs 
Performs a few tasks alone with assistant nearby 
Requires complete assistance 
Hygiene maintained well; gives aid to assistant 
Reasonably good hygiene with assistance, but does not provide assistant with significant 
help 
Unable to maintain proper hygiene with even maximum help 
Eating 
Normal 
Scale D. EATING AND FEEDING 
Follows a normal diet, but chewing and swallowing are labored 
Eats some hard foods routinely, but these require time and effort 
Liquids and soft foods handled with ease, hard foods occasionally eaten, but require 
great effort and much time 
Eats only liquids and soft foods; these are consumed very slowly 
Eating so impaired that a hospital setting is required to get adequate nutrition 
Feeding 
Normal 
Fully feed self with rare accidents, slower than normal 
Handles all feeding alone with moderate slowness; still may get assistance in specific 
situation (cutting meat in restaurant); accidents are not infrequent 
Performs most feeding activities alone, slowly and with effort; requires help with 
specific tasks (cutting meat, filling cup) 
Performs only a few tasks independently 
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Speech 
Normal 
Scale E. SPEECH 
Speech entirely adequate; minor voice disturbances present 
Speech easily understood, but voice or speech rhythm may be disturbed 
Communication accomplished with ease, although speech impairment detracts from 
content 
Speech can always be understood if listener pays close attention; both articulation and 
voice may be defective 
Speech always employed for communication, but articulation is still very poor; usually 
uses complete sentences 
Uses speech for most communication, but articulation is highly unintelligible; may 
have occasional difficulty in initiating speech; usually speaks in single words or short 
phrases 
Attempts to use speech for communication, but has difficulty in initiating vocalization; 
may stop speaking in middle of phrase and be unable to continue 
Vocalizes to call attention to self 
Vocalizes but rarely for communicative purposes 
Does not vocalize at all 
APPENDIX B 





















Putting on a shirt 
Managing visible buttons; 1 in button 
Managing visible buttons; 8 in button 
Opening and closing a zipper 
Tying a bow 
Cutting with a knife 
Using a fork 
Pouring water into a glass 
Squeezing toothpaste from a tube 
Dialing a telephone 
Opening and closing a safety pin 
Opening and closing a door 
Opening an envelope 
Drinking from a glass with a straw 
Prolonged vocalization 
Washing hands; using dominant hand 
using nondominant hand 
Putting on gloves; using dominant hand 
















































*Scores are obtained by averaging two timed trials for all tests with the exception of 
the toothpaste and drinking tests where one timed trial is used. 
tFor a complete description of SADLE tests see: POTVIN, A. R.: The Effects of Age, 
Motivation and Learning on Performance in the Quantitative Examination of 
Neurological Function. Ph.D. Thesis, University of Michigan, 1971. 
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